PHO Enrolment Collection | HQSC

The PHO Enrolment Collection was established in 2005 to provide a national collection that holds Primary Healthcare System (PHCS) patient enrolment data for the following uses:

to assist PHOs, the Ministry of Health, Te Whatu Ora and Te Aka Whai Ora in reporting and monitoring patient enrolment under the PHCS
to provide PHOs, the Ministry of Health, Te Whatu Ora and Te Aka Whai Ora and health researchers with population data to assist with population health research
to assist PHOs in examining and improving the quality of their enrolment information.

Data source

Name	Description	Data sources	Responsible organisation(s)	Measure methodology last updated
People aged 12–44 dispensed a combined budesonide + formoterol inhaler	This indicator shows the number and percent of people aged 12-44 years who were regularly dispensed SMART Formoterol/Budesonide therapy. Regular dispensing was defined as dispensing in two or more quarters in the year. This indicator measures uptake of this inhaler, relative to other asthma inhalers. Specifically, of all people who were dispensed any asthma inhaler (SABA, LABA, ICS or LABA/ICS combination), what percentage were dispensed a combined budesonide + formoterol inhaler.	Pharmaceutical Collection (PHARMS), PHO Enrolment Collection	Health Quality & Safety Commission \| Te Tāhū Hauora	September 2025
Dispensed a urate-lowering therapy	This measure shows the percentage of people with identified gout who received urate-lowering therapy at least once in a year. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy continuously and long term.	National Minimum Dataset, Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ	Health Quality & Safety Commission \| Te Tāhū Hauora
People dispensed oxycodone one or more times in a year, rate per 1,000	This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had oxycodone dispensed to them by a community pharmacy, by year (2019 to 2023), ethnic group, age group, and gender.	Pharmaceutical Collection (PHARMS), PHO Enrolment Collection	Health Quality & Safety Commission \| Te Tāhū Hauora	November 2025
People dispensed morphine one or more times in a year, rate per 1,000	This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had morphine dispensed to them by a community pharmacy, by year (2019 to 2023), ethnic group, age group, and gender.	Pharmaceutical Collection (PHARMS), PHO Enrolment Collection	Health Quality & Safety Commission \| Te Tāhū Hauora	November 2025
People dispensed a strong opioid who had a public hospital event in the 8 days prior to dispensing, rate per 1,000	This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had received a strong opioid and had a public hospital event in the eight days prior to dispensing of a strong opioid during the calendar year. Data is presented by year (2019 to 2023), ethnic group, age, gender and health district.	National Minimum Dataset (NMDS), National Non-Admitted Patient Collection (NNPAC), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection	Health Quality & Safety Commission \| Te Tāhū Hauora	November 2025
People dispensed fentanyl for 6 or more weeks, rate per 1,000	This indicator shows the number and rate per 1,000 of the PHO-enrolled population who had fentanyl dispensed to them by a community pharmacy for six or more weeks in a year (2019 to 2023).	Pharmaceutical Collection (PHARMS), PHO Enrolment Collection	Health Quality & Safety Commission \| Te Tāhū Hauora	November 2025
Regularly dispensed a urate-lowering therapy	This measure shows the percentage of people with identified gout who received urate-lowering therapy regularly. Long-term urate-lowering therapy is used to prevent gout flares and prevent tophus formation, bony erosions and permanent disability in people with gout. Many studies have demonstrated underutilisation of urate-lowering therapy.	National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ	Health Quality & Safety Commission \| Te Tāhū Hauora
Serum urate test within six months of urate-lowering therapy	This measure shows the percentage of people who had serum urate testing in the six months following urate-lowering therapy dispensing. Best practice guidelines recommend that people with gout who are prescribed urate-lowering therapy should have their serum urate level monitored at least every six months. Long-term urate-lowering therapy is not recommended for people with asymptomatic hyperuricaemia.	National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ	Health Quality & Safety Commission \| Te Tāhū Hauora
Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug without urate-lowering therapy	This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs), but not dispensed urate-lowering therapy in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. This measure may reflect people experiencing acute gout flares who are not on long-term preventive therapy for gout. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease.	National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ	Health Quality & Safety Commission \| Te Tāhū Hauora
Dispensed prednisone, colchicine or a non-steroidal anti-inflammatory drug	This measure shows the percentage of people with identified gout who were dispensed any of colchicine, prednisone or funded non-steroidal anti-inflammatory drugs (NSAIDs) in a year. Acute gout flares are treated with colchicine, oral corticosteroids such as prednisone or NSAIDs. Gout management guidelines state that people experiencing frequent (two or more) acute gout flares per year should be offered long-term urate-lowering therapy. Although NSAIDs are effective at treating acute gout flares, these medicines have considerable side effects including kidney injury and peptic ulcer disease.	National Minimum Dataset (NMDS), Pharmaceutical Collection (PHARMS), PHO Enrolment Collection, Mortality Collection, NZ Cancer Registry, Ministry of Health, National Population Projection - Stats NZ	Health Quality & Safety Commission \| Te Tāhū Hauora

Subscribe to PHO Enrolment Collection